Evidence map›Paper›PMID 38225450›Full record

ArticlePediatric research2024

Neuroprotective effects of maternal melatonin administration in early-onset placental insufficiency and fetal growth restriction.

Atul Malhotra, Anna K A A Rocha, Tamara Yawno, Amy E Sutherland, Beth J Allison, Ilias Nitsos, Yen Pham, Graham Jenkin, Margie Castillo-Melendez, Suzanne L Miller

Open access · hybridAbstract read
In one paragraph

Article in Pediatric research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
21.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Atul Malhotra *The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia. atul.malhotra@monash.edu.ORCID 0000-0001-9664-4182
Anna K A A Rocha *The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.
Tamara YawnoThe Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.
Amy E SutherlandThe Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.
Beth J AllisonThe Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.
Ilias NitsosThe Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.
Yen PhamThe Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.
Graham JenkinThe Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.
Margie Castillo-Melendez *The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.
Suzanne L Miller *The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.
Hudson Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEarly-onset fetal growth restriction (FGR) is associated with adverse outcomes. We hypothesised that maternal melatonin administration will improve fetal brain structure in FGR.

methodsSurgery was performed on twin-bearing ewes at 88 days (0.6 gestation), and FGR induced in one twin via single umbilical artery ligation. Melatonin was administered intravenously (6 mg/day) to a group of ewes commencing on day of surgery until 127 days (0.85 gestation), when the ewe/fetuses were euthanized, and fetal brains collected.

resultsStudy groups were control (n = 5), FGR (n = 5), control+melatonin (control+MLT; n = 6) and FGR+melatonin (FGR + MLT; n = 6). Melatonin administration did not significantly alter fetal body or brain weights. Myelin (CNPase+) fibre density was reduced in FGR vs. control animals in most brain regions examined (p < 0.05) and melatonin treatment restored CNPase fibre density. Similar but less pronounced effect was seen with mature myelin (MBP+) staining. Significant differences in activated microglia (Iba-1) activity were seen between lamb groups (MLT mitigated FGR effect) in periventricular white matter, subventricular zone and external capsule (p < 0.05). Similar effects were seen in astrogliosis (GFAP) in intragyral white matter and cortex.

conclusionsMaternal melatonin administration in early onset FGR led to improved myelination of white matter brain regions, possibly mediated by decreased inflammation. IMPACT: Maternal melatonin administration might lead to neuroprotection in the growth-restricted fetus, possibly via dampening neuroinflammation and enhancing myelination. This preclinical study adds to the body of work on this topic, and informs clinical translation. Neuroprotection likely to improve long-term outcomes of this vulnerable infant group.

Indexed as

BrainFetal Growth RetardationMelatoninNeuroprotective AgentsPlacental InsufficiencyAnimalsDisease Models, AnimalFemaleMicrogliaMyelin SheathPregnancySheepMelatoninNeuroprotective Agents

Identifiers

PMID38225450
PMCPMC11126390
OpenAlexW4390878913

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.